CDKN2A and acute lymphoblastic leukemia: Thus, a significant proportion of refractory ALL patients in the TACL study [8, 9] may have harbored IKZF1 deletion and/or biallelic loss of CDKN2A, although the gene copy number alteration profile was not described.